Jones Day
Praised for its ‘great negotiating skills’, language capabilities and international resources, Jones Day handles a significant amount of work relating to HKEX IPOs, global offerings, follow-on offerings, regulatory compliance and public M&A. The team has gained particular acclaim for its work in biotech/life sciences and hi-tech sectors, with ’technically sound and commercially astute’ Joelle Lau a popular choice among Chinese issuers and banks on listings in the space. The ‘responsive and always reachable’ Charles Chau , who co-heads the team alongside Lau, is also noted for his work in the bioscience sector, including on issuer side private placements, IPOs, as well as current work for a proposed SPAC focused on biotech/TMT targets.
Legal 500 Editorial commentary
Testimonials
Collated independently by Legal 500 research team.
- 'Jones Day has great experience in capital market area. The lawyers have great negotiating skills and are able to provide valuable advice.'
- 'Effectively bilingual team with particular depth of experience in the biosciences space.'
- 'Charles Chau is responsive and always reachable.'
- 'Joelle Lau is technically sound, very hands on, proactive, commercially astute and effectively bilingual.'
Key clients
- GenScript Biotech Corporation
- Legend Biotech Corporation
- Jefferies LLC
- Guotai Junan Capital Limited
- New Hope Group Co Ltd
- China Galaxy International Financial Capital Limited
- China International Capital Corporation Limited (CICC)
- China International Capital Corporation Hong Kong Securities Limited
- China Everbright Securities International Limited
- CMBC International Capital Limited
- Shanghai Junshi Biosciences Co., Ltd
- Halcyon Capital Limited
- Greater Bay Area Homeland Investments Limited
- BOC International (Asia) Limited
- Huatai Financial Holdings (Hong Kong) Ltd
- BNP Paribas Securities (Asia) Limited
- Shanghai Junshi Biosciences Co., Ltd.
- UBS AG Hong Kong Branch
- UBS Securities Hong Kong Limited
- OMERS Administration Corporation
- The Hong Kong and China Gas Company Limited
- Samson Paper Holdings Limited
Work highlights
- Represented GenScript Biotech Corporation in Legend Biotech’s various fundraising activities by way of private placements and a registered direct offering involving various counterparties, including Hillhouse Investment Management, Ltd., RA Capital Management, L.P. and Legend Capital Group, etc.
- Representing Samson Paper Holdings Limited on its $385m Bermuda/Mainland China/Hong Kong cross-border restructuring deal.
- Advised a SPAC, on its proposed HK$1bn IPO and listing on the Main Board of The Hong Kong Stock Exchange.
Practice head
The lawyer(s) leading their teams.
Joelle Lau, Charles Chau